Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The neurodegenerative aspects of chronic progressive multiple sclerosis (MS) have received increasing attention in recent years, since anti-inflammatory and immunosuppressive treatment strategies have largely failed. However, successful neuroprotection and/or neuroregeneration in MS have not been demonstrated yet. Encouraged by the multifaceted neuroprotective effects of recombinant human erythropoietin (rhEPO) in experimental models, we performed an investigator-driven, exploratory open label study (phase I/IIa) in patients with chronic progressive MS. Main study objectives were (i) evaluating safety of long-term high-dose intravenous rhEPO treatment in MS, and (ii) collecting first evidence of potential efficacy on clinical outcome parameters. Eight MS patients, five randomly assigned to high-dose (48,000 IU), three to low-dose (8000 IU) rhEPO treatment, and, as disease controls, two drug-naïve Parkinson patients (receiving 48,000 IU) were followed over up to 48 weeks: A 6-week lead-in phase, a 12-week treatment phase with weekly EPO, another 12-week treatment phase with bi-weekly EPO, and a 24-week post-treatment phase. Clinical and electrophysiological improvement of motor function, reflected by a reduction in expanded disability status scale (EDSS), and of cognitive performance was found upon high-dose EPO treatment in MS patients, persisting for three to six months after cessation of EPO application. In contrast, low-dose EPO MS patients and drug-naïve Parkinson patients did not improve in any of the parameters tested. There were no adverse events, no safety concerns and a surprisingly low need of blood-lettings. This first pilot study demonstrates the necessity and feasibility of controlled trials using high-dose rhEPO in chronic progressive MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Compston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743
Gold, R. (2006) · Brain · doi:10.1093/brain/awl075 · Cited by 1,017
Self-citationEmerging biological roles for erythropoietin in the nervous system
Brines, M., & Cerami, A. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1687 · Cited by 523
Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients
Sfagos, C., Makis, A. C., Chaidos, A., Hatzimichael, E. C., Dalamaga, A., Kosma, K., & Bourantas, K. L. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1171oa · Cited by 84
Iron-deficient mice fail to develop autoimmune encephalomyelitis
Grant, S. M., Wiesinger, J. A., Beard, J. L., & Cantorna, M. T. (2003) · The Journal of Nutrition · doi:10.1093/jn/133.8.2635 · Cited by 78
Cited by
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Practice effects in healthy adults: A longitudinal study on frequent repetitive cognitive testing
Bartels, C., Wegrzyn, M., Wiedl, A., Ackermann, V., & Ehrenreich, H. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-118 · Cited by 444
Self-citationMotor learning promotes remyelination via new and surviving oligodendrocytes
Bacmeister, C. M., Barr, H. J., McClain, C. R., Thornton, M. A., Nettles, D., Welle, C. G., & Hughes, E. G. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0637-3 · Cited by 315
Miskowiak, K. W., Vinberg, M., Christensen, E. M., Bukh, J. D., Harmer, C. J., Ehrenreich, H., & Kessing, L. V. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.335 · Cited by 104
Self-citationEffects of Erythropoietin on Hippocampal Volume and Memory in Mood Disorders
Miskowiak, K. W., Vinberg, M., Macoveanu, J., Ehrenreich, H., Køster, N., Inkster, B., Paulson, O. B., Kessing, L. V., Skimminge, A., & Siebner, H. R. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.12.013 · Cited by 99
Self-citation
Metadata
- Authors
- Ehrenreich, H., Fischer, B., Norra, C., Schellenberger, F., Stender, N., Stiefel, M., Sirén, A.-L., Paulus, W., Nave, K.-A., Gold, R., & Bartels, C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-08-29
- Volume
- 130
- Issue
- 10
- Pages
- 2577-2588
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2115406568
- Cited by
- 236
- References
- 6
- FWCI
- 13.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.